Santen and Clearside Biomedical Enter into Research and Financial Pact

Santen, an Emeryville, Calif.-based subsidiary of Japan-based Santen Pharmaceuticals, has entered into a research collaboration agreement with Clearside Biomedical of Alpharetta, Georgia, a company in which Santen, along with other financial backers, is also making an investment. Specifically, Clearside’s “microinjection platform,” which provides access to the retina and choroid, just attracted $7.9 million in fresh funding from Santen, Mountain Group Capital, Hatteras Venture Partners, Georgia Research Alliance Fund, and Kenan Flagler Business School Private Equity Fund.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget